Replies to post #180105 on Biotech Values

[DewDiligence]

What does the term, de-immunized signify in this context? T.i.a.

[gdollasign]

PGS,
I appreciate the science in your answer and I rely on those types of answers as I wouldnt even pretend to have that depth of knowledge in that arena. So thanks.

...could be cleared out by the patient just as quickly, thereby negating the therapy.

May come across as naive but...how is that not known already? I get the lack of human dosing as a primary reason but that just seems like science....and determinable. Has this been mentioned by TR as a concern?

G$

[mcbio]

Trillium's drug is a fusion between an antibody's constant region and SIRPa. The fusion point is not a native sequence, and therefore can be recognized by the host's immune response (see DNDN). If this happens, the drug that gets infused could be cleared out by the patient just as quickly, thereby negating the therapy.

I take it you're aware Trillium actually has potential rights to several drugs now targeting SIRPa. See the second group of potential antibodies they recently acquired an option for exclusive rights here: http://www.trilliumtherapeutics.com/Documents/PressReleases/SCTPressRelease_2013_10_17_81053.pdf . Not clear to me that the newer antibodies have a "fusion" like the lead drug. In any event, I realize this is very early stage work and plenty could go wrong but at just over $100M fully-diluted market cap and one of the only public ways possible to play what sounds like an emerging target in CD47, I'll continue to take my chances, for better or worse.